SecBot SecBot
8-K ·Filed Jun 30, 2026

XERS

Xeris Biopharma Holdings, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001867096-26-000048
8-K context-dependent: Items 5.02, 7.01
Actionable Insight • Neutral

This filing contains only routine board and leadership changes with no financial or operational catalysts. Monitor upcoming quarterly results for any strategic shifts under the new chair/CEO structure.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$8.00
T+0 close · Jun 30, 2026 · via day close
Latest settled
+11.88%
T+60 · $8.95
Vs SPY
+8.92%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 1 $8.00entry
  2. T+1 · 5mo ago +3.50%α +3.63% · $8.28
  3. T+5 · 4mo ago +11.75%α +11.49% · $8.94
  4. T+20 · 4mo ago +4.75%α +6.94% · $8.38
  5. T+60 · 8w ago +11.88%α +8.92% · $8.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Xeris Biopharma announced routine board governance changes: CEO John Shannon was appointed Chair of the Board, Marla Persky transitioned to Lead Independent Director, and Nerissa Kreher, M.D., was added as an independent director. The board expanded from seven to eight members. No financial data or operational updates were provided.

Key Facts

  • Board expanded from 7 to 8 members with the appointment of Nerissa Kreher, M.D., effective July 1, 2026
  • CEO John Shannon appointed Chair of the Board, effective July 1, 2026
  • Marla Persky designated as Lead Independent Director, effective July 1, 2026
  • Dr. Kreher received an initial equity award with aggregate grant date fair value of approximately $450,000
  • Dr. Kreher is independent under Nasdaq listing standards and has extensive biotech CMO experience

Financial Impact

No financial impact; routine governance changes with no material financial data disclosed

Risk Factors

  • No material risks identified from this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001867096-26-000048
Exhibit: exh991boardappointmentpres.htm0001867096-26-000048
Document: 0001867096-26-000048-index-headers.html0001867096-26-000048
Document: 0001867096-26-000048-index.html0001867096-26-000048
Document: 0001867096-26-000048.txt0001867096-26-000048

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026